Bispecific antibody CAP256.J3LS targets V2-apex and CD4-binding sites with high breadth and potency-Reference-Cited by-同舟云学术

Bispecific antibody CAP256.J3LS targets V2-apex and CD4-binding sites with high breadth and potency

Published:2023-02-02 Issue:1 Volume:15 Page:
ISSN:1942-0862
Container-title:mAbs
language:en
Short-container-title:mAbs

Author:

Zhang Baoshan¹,Gorman Jason¹,Kwon Young D.¹,Pegu Amarendra¹,Chao Cara W.¹,Liu Tracy¹,Asokan Mangaiarkarasi¹,Bender Michael F.¹,Bylund Tatsiana¹,Damron Leland¹,Gollapudi Deepika¹,Lei Paula¹,Li Yile¹,Liu Cuiping¹,Louder Mark K.¹,McKee Krisha¹,Olia Adam S.¹,Rawi Reda¹,Schön Arne²,Wang Shuishu¹,Yang Eun Sung¹,Yang Yongping¹,Carlton Kevin¹,Doria-Rose Nicole A.¹,Shapiro Lawrence³,Seaman Michael S.⁴,Mascola John R.¹,Kwong Peter D.¹³^ORCID

Affiliation:

1. Vaccine Research Center, NIAID, National Institutes of Health, Bethesda, MD, USA

2. Department of Biology, Johns Hopkins University, Baltimore, MD, USA

3. Department of Biochemistry, Columbia University, New York, NY, USA

4. Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA

Publisher

Informa UK Limited

Subject

Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/19420862.2023.2165390

Reference43 articles.